Study Supports PCa Screening With MRI vs TRUS-biopsy
Population-based prostate cancer screening with MRI has a significantly better risk/benefit ratio.
(HealthDay News) — Magnetic resonance imaging (MRI)-targeted biopsy could reduce the need for biopsies and overdiagnosis with low-grade prostate cancer, according to a study presented at the annual meeting of the European Association of Urology, held from March 24 to 28 in London.
Arnout Alberts, MD, from the Erasmus Medical Center in Rotterdam, Netherlands, and colleagues compared screening using sextant transrectal ultrasound-guided biopsy (6-TRUS-Bx), 12-core TRUS biopsy (12-TRUS-Bx), and a MRI ± target biopsy (MRI ± TBx) strategy in the fifth screening round of the European Randomized Study of Screening for Prostate Cancer. Men with a prostate-specific antigen ≥3.0 ng/mL received 6-TRUS-Bx (177 men) or chose to receive a multiparametric MRI as part of the MRI side study (158 men). Participants in the side study received 12-TRUS-Bx with performance blinded for MRI results.
The researchers found that 70% of men in the side study had no suspicious lesions on MRI and did not receive TBx. The detection rate of high-grade prostate cancer was comparable for 6-TRUS-Bx, 12-TRUS-Bx, and MRI ± TBx (10%, 12%, and 11%, respectively). The detection rate for low-grade prostate cancer was 28% for 12-TRUS-Bx, which was significantly higher than 17% for 6-TRUS-Bx; the detection rate for MRI ± TBx was significantly lower (7%).
"Population-based prostate cancer screening with MRI instead of TRUS-biopsy has a significantly better risk/benefit ratio and could offer real benefits to men at risk of prostate cancer," Alberts said in a statement.
- MRI use may “change the equation” for prostate cancer screening [press release]. European Association of Urology National Meeting. March 24-28 2017.